CureVac aims to make reasonable profit on COVID-19 vaccine_老虎社区_美港股上老虎

CureVac aims to make reasonable profit on COVID-19 vaccine

Douglas W. House2020-08-17

Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:CVAC) says it plans on earning an "ethical" profit margin based on a competitive price. CFO Pierre ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

tin13
·2020-08-17
说说你对这篇新闻的看法...
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2060617053?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2020-08-17 06:58","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2060617053","market":"us","top_or_hot":-1,"title":"CureVac aims to make reasonable profit on COVID-19 vaccine","media":"Douglas W. House","content":"<div>\n<p>Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:CVAC) says it plans on earning an \"ethical\" profit margin based on a competitive price.\nCFO Pierre ...</p>\n\n<a href=\"https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CureVac aims to make reasonable profit on COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCureVac aims to make reasonable profit on COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-08-17 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine><strong>Douglas W. House</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:CVAC) says it plans on earning an \"ethical\" profit margin based on a competitive price.\nCFO Pierre ...</p>\n\n<a href=\"https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://seekingalpha.com/news/3606046-curevac-aims-to-make-reasonable-profit-on-covidminus-19-vaccine","article_id":"2060617053","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2060617053","pubTimestamp":1597618697,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:C","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生","MRNA":"Moderna, Inc.","AZN":"阿斯利康","CVAC":"CureVac B.V."},"translate_title":"CureVac的目标是在COVID-19疫苗上获得合理利润","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"CVAC":0.9,"JNJ":0.9,"MRNA":0.9},"content_text":"Ruling out selling its mRNA-based COVID-19 vaccine at cost, if approved, fresh IPO CureVac (NASDAQ:CVAC) says it plans on earning an \"ethical\" profit margin based on a competitive price.\nCFO Pierre Kemula declined to disclose what the expected margin will be but said the unit price will be dose-dependent not cost-related.\nRival COVID-19 vaccine developers AstraZeneca (NYSE:AZN) and the University of Oxford have floated $3 - 4 per dose for their offering while Johnson & Johnson's (NYSE:JNJ) will be $10 per dose, reflecting their previously stated commitment not to profit from their respective vaccines during the pandemic. Fellow mRNA vaccine developer Moderna (NASDAQ:MRNA) has priced some of its shots at $74 per course.\nTalks between the EU and company for a committed supply of product are in process.\nEarlier this year, the German government invested €300M in the company, representing a 23% stake, aimed at blocking any foreign takeover attempt.\nThe company is working with Tesla Grohmann Automation, a subsidiary of the electric car maker, to develop RNA printers to help manufacture the vaccine. At present, there are eight prototypes, each capable of making 0.5 gm per week.\nClick to subscribe to real-time analytics on CVACNow read: Retirement: Where You Could Invest Your Cash Today »","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":970935483,"gmtCreate":1597629134742,"gmtModify":1704216076615,"author":{"id":"3558559727742226","authorId":"3558559727742226","name":"tin13","avatar":"https://static.tigerbbs.com/259a99455556292cf7e7a111521464f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3558559727742226","authorIdStr":"3558559727742226"},"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/970935483","repostId":2060617053,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}